Probiodrug Ag

Kathrin Gans

Hans-Ulrich Demuth

Stephan Schilling

Jens-Ulrich Rahfeld

Sonja Kampfer

Holger Cynis

Martin Kleinschmidt

Anita Reisenauer-Schaupp

Ulrich Heiser

Torsten Hoffmann

Michael Thormann

Andreas Treml

Michael Almstetter

Robert Sommer

Michael Wermann

Ulf-Torsten Gaertner

Antje Hamann

Astrid Kehlen

Daniel Friedrich

Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).

Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE)

Diagnostic assays for the diagnosis of amyloidosis, in particular, Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.

Diagnostic antibody assay

The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.

Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions

Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described.

The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.

Antibodies specific for N-terminal truncated and pyroglutamate modified amyloid-beta peptides

Growing community of inventors

Halle/Saale, Germany

Kathrin Gans